BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37558975)

  • 1. ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA).
    Sahoo TP; Desai C; Agarwal S; Rauthan A; Dhabhar B; Biswas G; Batra S; Saha R; Philip A; Agarwal V; Dattatreya PS; Mohapatra PN; Deshmukh C; Bhagat S; Patil S; Barkate H
    BMC Cancer; 2023 Aug; 23(1):737. PubMed ID: 37558975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
    Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer.
    Hall J; Zanotti G; Kim R; Krulewicz S; Leith A; Bailey A; Liu FX; Kearney M
    Future Oncol; 2021 Jun; 17(17):2169-2182. PubMed ID: 33631973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
    Rini BI; Battle D; Figlin RA; George DJ; Hammers H; Hutson T; Jonasch E; Joseph RW; McDermott DF; Motzer RJ; Pal SK; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
    J Immunother Cancer; 2019 Dec; 7(1):354. PubMed ID: 31856918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma.
    Park KY; Hefti HO; Liu P; Lugo-Cintrón KM; Kerr SC; Beebe DJ
    Integr Biol (Camb); 2021 Dec; 13(11):259-268. PubMed ID: 34931665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the management of advanced and metastatic renal cell carcinoma: joint consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
    Poon DMC; Chan CK; Chan K; Chu WH; Kwong PWK; Lam W; Law KS; Lee EKC; Liu PL; Sze HCK; Wong JHM; Chan ESY
    Hong Kong Med J; 2022 Dec; 28(6):475-481. PubMed ID: 35815480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
    Markham A
    Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
    Puente J; García Del Muro X; Pinto Á; Láinez N; Esteban E; Arranz JÁ; Gallardo E; Méndez MJ; Maroto P; Grande E; Suárez C
    Target Oncol; 2016 Apr; 11(2):129-41. PubMed ID: 26706236
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).
    Méndez-Vidal MJ; Lázaro Quintela M; Lainez-Milagro N; Perez-Valderrama B; Suárez Rodriguez C; Arranz Arija JÁ; Peláez Fernández I; Gallardo Díaz E; Lambea Sorrosal J; González-Del-Alba A
    Clin Transl Oncol; 2023 Sep; 25(9):2732-2748. PubMed ID: 37556095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
    Cetin B; Wabl CA; Gumusay O
    Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
    Pal SK; McGregor B; Suárez C; Tsao CK; Kelly W; Vaishampayan U; Pagliaro L; Maughan BL; Loriot Y; Castellano D; Srinivas S; McKay RR; Dreicer R; Hutson T; Dubey S; Werneke S; Panneerselvam A; Curran D; Scheffold C; Choueiri TK; Agarwal N
    J Clin Oncol; 2021 Nov; 39(33):3725-3736. PubMed ID: 34491815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
    Al-Salama ZT; Keating GM
    Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region.
    So TH; Sharma S; Parij R; Spiteri C; Chawla E; Pandey P; Rajasekaran T
    Expert Rev Anticancer Ther; 2023; 23(8):853-863. PubMed ID: 37458169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.